Paliperidone extended release

CNS Drugs. 2007;21(5):417-25; discussion 426-7. doi: 10.2165/00023210-200721050-00005.


Paliperidone extended release (ER) is an atypical antipsychotic that is administered orally once daily to provide consistent plasma drug concentrations over 24 hours in adult patients with schizophrenia. In four well controlled trials, once-daily administration of paliperidone ER 3-12 mg over 6 weeks was more effective than placebo in reducing the positive and negative symptoms experienced by adult patients with schizophrenia, including elderly individuals aged > or =65 years. Patients with schizophrenia treated with paliperidone ER achieved greater improvement in clinically relevant measures of personal and social functioning and disease severity than those who received placebo. In another well controlled trial, paliperidone ER demonstrated superior efficacy to placebo in preventing the recurrence of schizophrenia symptoms. In patients who experienced a recurrence, time to recurrence was delayed with paliperidone ER compared with placebo triangle Paliperidone ER 3-12 mg/day for 6 weeks was generally well tolerated by patients with schizophrenia in clinical trials.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacokinetics
  • Antipsychotic Agents / therapeutic use
  • Biotransformation
  • Clinical Trials as Topic
  • Delayed-Action Preparations
  • Humans
  • Isoxazoles / administration & dosage*
  • Isoxazoles / adverse effects
  • Isoxazoles / pharmacokinetics
  • Isoxazoles / therapeutic use
  • Paliperidone Palmitate
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / therapeutic use
  • Schizophrenia / drug therapy
  • Tissue Distribution


  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Isoxazoles
  • Pyrimidines
  • Paliperidone Palmitate